

1 Running title: SARS-CoV-2 RNA in late 2019

2 Keywords: COVID-19, Sars-cov-2

3

4 **Retrospective Pooled Screening for SARS-CoV-2 RNA in late 2019**

5

6 Catherine A. Hogan, MD, MSc^{1,2}, Natasha Garamani, BSc¹, Malaya K. Sahoo, PhD¹, ChunHong

7 Huang, MD¹, James Zehnder, MD¹, Benjamin A. Pinsky, MD, PhD^{1,2,3*}

8

9 ¹Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

10 ²Clinical Virology Laboratory, Stanford Health Care, Stanford, CA, USA

11 ³Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford

12 University School of Medicine, Stanford, CA, USA

13

14

15 **Abstract (49 words)**

16 Reports have emerged documenting earlier SARS-CoV-2 cases than previously recognized. To
17 investigate this possibility in the Bay Area, we retrospectively tested 1,700 samples from
18 symptomatic individuals for the last 2 months of 2019. No SARS-CoV-2 positive pools were
19 identified, consistent with limited transmission in this population at this time.

20

21 **Text (791 words)**

22 **Introduction**

23 The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the
24 subsequent coronavirus disease 2019 (COVID-19) pandemic has revealed the critical importance
25 of sentinel surveillance mechanisms for the rapid identification and response to new human
26 pathogens. Phylogenetic analyses of SARS-CoV-2 suggest the virus first emerged weeks if not
27 months before the World Health Organization (WHO) was notified of the original cluster of
28 pneumonia cases associated with individuals who visited a wet market in Wuhan City, Hubei
29 Province, in the People's Republic of China (1). Consistent with these estimates, an unconfirmed
30 report in the lay press indicated the diagnosis of a COVID-19 case in Hubei Province on 17
31 November 2019 (2). Furthermore, retrospective testing in France detected SARS-CoV-2 in a
32 respiratory sample collected December 27 2019, a month earlier than official cases were reported
33 in the country (3). The San Francisco Bay Area presented among the first documented cases of
34 community transmission in the U.S. (4), and a 6 February 2020 autopsy report from the Santa
35 Clara County coroner confirmed detection of SARS-CoV-2 (5). Taken together, these reports
36 suggest the possibility of earlier viral spread than previously recognized in Northern California.
37 We recently employed a pooling strategy to leverage high-volume screening for community
38 circulation of SARS-CoV-2 in individuals negative by routine respiratory virus testing during the
39 first two months of 2020 (4). In this study, we extend pooled SARS-CoV-2 screening to include
40 the last two months of 2019 to investigate possible early circulation of SARS-CoV-2 in this area.

41

42 **Methods**

43 We performed a retrospective study that evaluated all available nasopharyngeal swab samples
44 collected between 31 October 2019 to 31 December 2019 at Stanford Health Care from
45 inpatients and outpatients that were negative by routine respiratory virus testing (Respiratory
46 Pathogen Panel, Genmark Diagnostics or Xpert Xpress Flu/RSV, Cepheid) and that had not been
47 tested for SARS-CoV-2. Pools were created by combining ten individual nasopharyngeal
48 samples, and screening was performed using reverse transcriptase polymerase chain reaction
49 (RT-PCR) targeting the nucleocapsid (*N2*) gene (6). This study was approved by the Stanford
50 institutional review board (IRB), and individual patient consent was waived.

51

52 **Results**

53 A total of 1700 individual nasopharyngeal specimens, corresponding to 170 pools, were included
54 for SARS-CoV-2 testing. Of these, 841 samples were previously tested and negative by the
55 Respiratory Pathogen Panel, and 859 were negative by the Xpert Xpress Flu/RSV. No SARS-
56 CoV-2 positive pools were identified. The study time period corresponded to the onset of the
57 2019-2020 respiratory virus season with an increasing number of cases of influenza A, influenza
58 B, and respiratory syncytial virus (RSV), and varying frequency of other seasonal viruses (Figure
59 1A 1B).

60

61 **Discussion**

62 In this study, 1,700 nasopharyngeal samples collected from symptomatic individuals in the last
63 two months of 2019 were screened by pooled testing, and no case of COVID-19 was detected.
64 Phylogenetic analyses have estimated the emergence of SARS-CoV-2 to have occurred between
65 6 October 2019 and 11 December 2019 (7). Given this timeline, there has been growing interest

66 to retrospectively identify “patient zero” in different geographic areas to better understand the
67 spread of SARS-CoV-2, and to inform current and future surveillance strategies for emerging
68 infectious diseases. Indeed, given the high volume of international travel prior to implementation
69 of travel restrictions, travel-associated COVID-19 cases may have occurred in the U.S. earlier
70 than previously recognized (8). However, monitoring for early community transmission of
71 COVID-19 in the U.S was challenging due its similar clinical presentation to other respiratory
72 virus infections, and overlap with the annual respiratory virus season. Strict indications for
73 testing based on specific risk factors, coupled with limited testing capacity, further limited local
74 COVID-19 case finding and contact tracing efforts (9, 10). Despite these shortcomings, this and
75 previous work indicate that in the catchment area of our institution, symptomatic individuals
76 without risk factors and diagnosed with SARS-CoV-2 infection began presenting to medical
77 attention at the end of February 2020 (4, 11).

78
79 This study is limited by its sampling from a single institution, corresponding to a population that
80 may not be representative of the underlying area as a whole. Further retrospective SARS-CoV-2
81 RT-PCR screening using specimens collected at other institutions throughout the U.S. will be
82 necessary to fully understand early community transmission in this country. This work will
83 complement phylogenetic viral sequence analysis and large-scale seroprevalence studies to
84 characterize the regional and national emergence of SARS-CoV-2. Furthermore, it is possible
85 that the use of pooled testing have led to lower sensitivity; however, pool sizes of 10 samples
86 have been shown to maintain high performance compared to individual samples (12).

87

88 In summary, we employed a pooled screening strategy to investigate local community
89 transmission of SARS-CoV-2 in late 2019 during the onset of the respiratory virus season. No
90 COVID-19 cases were identified, consistent with limited transmission in this population at this
91 time.

92
93 Dr. Hogan is an infectious diseases physician and medical microbiologist, currently a Visiting
94 Instructor and a Global Health Diagnostics Fellow at the Stanford Department of Pathology. Her
95 research interests include novel and point-of-care diagnostic methods, clinical impact of
96 diagnostic methods and tropical medicine.

97

98 **Funding:** none

99 **References**

100

101 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from
102 Patients with Pneumonia in China, 2019. *New England Journal of Medicine*. 2020;382(8):727-
103 33.

104 2. Ma J. Coronavirus: China's first confirmed Covid-19 case traced back to November 17.
105 *South China Morning Post*; 2020 [May 13 2020]; Available from:
106 [https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-](https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back)
107 [covid-19-case-traced-back](https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back).

108 3. Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar JR, et al.
109 SARS-CoV-2 was already spreading in France in late December 2019. *Int J Antimicrob Agents*.
110 2020 May 3:106006.

111 4. Hogan CA, Sahoo MK, Pinsky BA. Sample Pooling as a Strategy to Detect Community
112 Transmission of SARS-CoV-2. *JAMA*. 2020 Apr 6.

113 5. Santa Clara County Public Health. County of Santa Clara Identifies Three Additional
114 Early COVID-19 Deaths. 2020 [May 13 2020]; Available from:
115 <https://www.sccgov.org/sites/covid19/Pages/press-release-04-21-20-early.aspx>.

116 6. Bulterys PL, Garamani N, Stevens B, Sahoo MK, Huang C, Hogan CA, et al.
117 Comparison of a Laboratory-Developed Test Targeting the Envelope gene with three Nucleic
118 Acid Amplification Tests for Detection of SARS-CoV-2. *Journal of Clinical Virology*. 2020
119 2020/05/08/:104427.

120 7. van Dorp L, Acman M, Richard D, Shaw LP, Ford CE, Ormond L, et al. Emergence of
121 genomic diversity and recurrent mutations in SARS-CoV-2. *Infection, Genetics and Evolution*.
122 2020 2020/05/05/:104351.

- 123 8. News A. Disaster in motion: Where flights from coronavirus-ravaged countries landed in
124 US. 2020 [May 13 2020]; Available from: [https://abcnews.go.com/Health/disaster-motion-](https://abcnews.go.com/Health/disaster-motion-flights-coronavirus-ravaged-countries-landed-us/story?id=70025470)
125 [flights-coronavirus-ravaged-countries-landed-us/story?id=70025470](https://abcnews.go.com/Health/disaster-motion-flights-coronavirus-ravaged-countries-landed-us/story?id=70025470).
- 126 9. Centers for Disease Control and Prevention (CDC). Evaluating and Testing Persons for
127 Coronavirus Disease 2019 (COVID-19). 2020 [May 13 2020]; Available from:
128 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html>.
- 129 10. Sharfstein JM, Becker SJ, Mello MM. Diagnostic Testing for the Novel Coronavirus.
130 JAMA. 2020 Mar 9. doi: 10.1001/jama.2020.3864. [Epub ahead of print] Mar 9.
- 131 11. Zwald ML, Lin W, Sondermeyer Cooksey GL, Weiss C, Suarez A, Fischer M, et al.
132 Rapid Sentinel Surveillance for COVID-19 - Santa Clara County, California, March 2020.
133 MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):419-21.
- 134 12. Yelin I, Aharony N, Shaer Tamar E, Argoetti A, Messer E, Berenbaum D, et al.
135 Evaluation of COVID-19 RT-qPCR test in multi-sample pools. Clin Infect Dis. 2020 May 2.

136

137 Address for correspondence: Benjamin A. Pinsky, Stanford Health Care Clinical Virology

138 Laboratory, 3375 Hillview, Room 2913, Palo Alto, CA, USA, 94304, bpinsky@stanford.edu

139


140

141 Figure 1. Respiratory surveillance November and December 2019. A) Influenza A, influenza B,
142 respiratory syncytial virus (RSV), and seasonal coronaviruses, including HKU1, OC43, NL63,
143 229E. B) Adenovirus, human metapneumovirus (hMPV), parainfluenza viruses 1, 2, 3, and 4,
144 and rhinovirus/enterovirus.

145

146

A.



B.

